Padronização de tratamento curativo da malária não grave experimental murina por Plasmodium berghei (NK65)

Abstract

Malaria, an infectious parasitic disease caused by the protozoan of the genus Plasmodium, is one of the biggest public health problems in the world. Antimalarial drugs are fundamental in the global control of this disease. In the experimental field, murine models are widely used to study different aspects of malaria. In this study, we sought to establish a therapeutic treatment for infection by Plasmodium berghei (strain NK65) in the C57BL/6 mouse, due to the difficulty in presenting efficient therapy with traditional medicines, such as chloroquine, and contributing to the development of effective and applicable treatments in rodent malaria models. Protocols were established with the combination of amodiaquine, artesunate, sulfadiazine, artemether and lumefantrine in different dosages and routes of administration to achieve a radical parasitological cure. The results found showed that combined treatment with artesunate (50mg/kg intraperitoneally) together with amodiaquine (24mg/kg via gavage) over seven days promoted the radical cure of C57BL/6 mice infected by PbNK65.